Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Double-Blind, Placebo Controlled. Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 Co-administered With MET097 in Adult Participants With Obesity or Overweight Including Participants With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo Controlled. Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 Co-administered With MET097 in Adult Participants With Obesity or Overweight Including Participants With Type 2 Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MET 097 (Primary) ; MET 233i (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Metsera

Most Recent Events

  • 28 Jul 2025 According to Metsera, Inc. media release, 12 week topline data expected by year-end 2025 or in early 2026.
  • 19 May 2025 According to Metsera, Inc. media release,five-week monotherapy data from this study is expected in Q2 2025,and five-week weight loss, tolerability, and pharmacokinetic data co-administration part are expected in late 2025.Additional monotherapy and co-administration readouts 12 week data planned in late 2025.
  • 16 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top